News
Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
- Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer's Disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying...
Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
Continued progress in lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™) GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the...
Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
Live moderated video webcast discussion with N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer on Tuesday, November 16th at 11:00 AM ET GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the...
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
- Dr. Lemere is a renowned translational researcher focused on understanding, preventing, and treating Alzheimer's disease - Company continues to advance evaluation of Trappsol® Cyclo™ toward Phase 2 study in Alzheimer's disease with investigational new...
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
Company engaged in ongoing initiatives to help raise awareness and provide information on research and support for patients and families GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing...
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
Sharon H. Hrynkow, PhD, Chief Scientific Officer, Senior Vice President of Medical Affairs to participate in a Moderated round-table discussion with academics and industrial experts on October 11, 2021 at 4:30 PM (CET) / 10:30 AM (EST) GAINESVILLE, Fla. - Cyclo...
Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
- Dr. Kjems is a leading global physician scientist with a proven pharma track record of drug development across multiple therapeutic areas, including chronic indications, oncology and rare diseases - - Gerald F. Cox, MD, PhD will continue offering clinical...
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
- Live webcast presentation on Wednesday, September 22nd at 10:45 AM ET GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through...
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Trappsol® Cyclo™ is not currently approved for any indication.
Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.